A fixed-dose combination (FDC) therapy primarily indicated for the management of painful diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor that targets the polyol pathway, a key contributor to diabetic nerve damage. Methylcobalamin is an active form of Vitamin B12 that supports nerve regeneration and myelin synthesis. Pregabalin is a gabapentinoid that modulates calcium channels to provide central analgesic and neuropathic pain relief. This combination offers a multi-modal approach targeting both the underlying pathophysiology and symptomatic pain relief in diabetic neuropathy.
Adult: One tablet (Epalrestat 150mg + Methylcobalamin 1500mcg + Pregabalin 150mg) orally, twice daily. May be initiated at a lower dose (e.g., pregabalin 75mg) in some patients and titrated.
Note: Administer orally with or without food. Swallow whole with a glass of water. Do not crush or chew. Can be taken after meals to minimize potential gastrointestinal discomfort. Adherence to a regular schedule is important for consistent pain control.
The combination works via complementary mechanisms. Epalrestat inhibits aldose reductase, the first enzyme in the polyol pathway, reducing the accumulation of sorbitol and fructose in nerves, which is implicated in osmotic stress, oxidative damage, and reduced nerve conduction velocity in hyperglycemia. Methylcobalamin acts as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase, essential for myelin synthesis, nucleic acid production, and nerve regeneration. It may also promote nerve repair. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters (e.g., glutamate, substance P, noradrenaline), thereby dampening central sensitization and neuropathic pain signaling.
Pregnancy: Pregnancy Category C (US FDA). Pregabalin: Animal studies showed teratogenicity. Epalrestat & Methylcobalamin: Insufficient data. Use only if potential benefit justifies potential fetal risk. Not recommended.
Driving: May impair ability to drive or operate machinery. Patients should not drive until they know how the medication affects them, especially during dose titration. Dizziness and somnolence are common.
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Potentiated sedation, dizziness, respiratory depression, and impaired motor skills. | Major |
| Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril, Enalapril) | Increased risk and severity of peripheral edema and angioedema. | Major |
| Thiazolidinediones (Pioglitazone, Rosiglitazone) | Additive risk of peripheral edema and weight gain. | Moderate |
| Levodopa | Methylcobalamin may reduce the efficacy of Levodopa in Parkinson's disease. | Moderate |
| Chloramphenicol | May antagonize the hematopoietic response to Methylcobalamin. | Moderate |
Same composition (Epalrestat (150mg) + Methylcobalamin (1500mcg) + Pregabalin (150mg)), different brands: